2023
Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization
Sun Y, Cui L, Lu Y, Tan J, Dong X, Ni T, Yan J, Guan Y, Hao G, Liu J, Zhang B, Wei D, Hong Y, He Y, Qi J, Xu B, Lu J, Zhang Q, Zhao S, Ji X, Du X, Zhang J, Liu J, Wang J, Huang Y, Huang D, Du Y, Vankelecom H, Zhang H, Chen Z. Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization. JAMA 2023, 329: 1460-1468. PMID: 37129654, PMCID: PMC10155063, DOI: 10.1001/jama.2023.5302.Peer-Reviewed Original ResearchConceptsRecurrent implantation failureFrozen-thawed embryo transferBiochemical pregnancy lossLive birthsImplant failurePlacebo groupPrednisone groupPreterm deliveryEmbryo transferPregnancy lossRisk of preterm deliveryRates of biochemical pregnancyEmbryo transfer cyclesGood-quality embryosLive birth rateLive birth outcomesTreatment of recurrent implantation failureStatistically significant between-group differencesHistory of 2Randomized clinical trialsProbability of implantationImmune-regulatory agentSignificant between-group differencesNeonatal complicationsWeeks gestation
2020
The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, Diamond MP, Krawetz SA, Usadi R, Baker VL, Coward RM, Huang H, Wild R, Masson P, Smith JF, Santoro N, Eisenberg E, Zhang H, Network R. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility And Sterility 2020, 113: 552-560.e3. PMID: 32111479, PMCID: PMC7219515, DOI: 10.1016/j.fertnstert.2019.11.008.Peer-Reviewed Original ResearchConceptsMonths of treatmentMale factor infertilityFactor infertilityLive birthsSemen parametersPlacebo groupPrimary outcomeSperm concentrationPlacebo-controlled trialLive birth rateCumulative live birthDNA fragmentationFemale partnersSperm DNA fragmentation indexLycopene dailyVivo pregnancyClomiphene citrateSecondary outcomesEntire cohortAsthenospermic menFertility centerIntrauterine inseminationMonth 4Tubal patencyClinical trials
2019
Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility
Huang H, Kuang H, Sun F, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PR, Christman GM, Hansen KR, Santoro N, Eisenberg E, Zhang H, Network E. Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility And Sterility 2019, 111: 1011-1019.e1. PMID: 30926125, PMCID: PMC6487215, DOI: 10.1016/j.fertnstert.2019.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack PeopleDouble-Blind MethodFemaleHumansInfertility, FemaleLeiomyomaPolycystic Ovary SyndromePrevalenceConceptsPolycystic ovary syndromeUnexplained infertilityUterine fibroidsLow prevalenceOvary syndromeDifferent body mass index (BMI) groupsBody mass index groupsHigher body mass indexHigher total testosteroneNormal uterine cavityAssessment-insulin resistanceBody mass indexRandomized clinical trialsCurrent alcohol usersPrevalence of womenTotal testosteroneCurrent smokersInfertile womenLarge fibroidsMass indexInfertile patientsInsulin resistanceUterine cavityClinical trialsLower percentage
2017
Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial
Wu XK, Stener-Victorin E, Kuang HY, Ma HL, Gao JS, Xie LZ, Hou LH, Hu ZX, Shao XG, Ge J, Zhang JF, Xue HY, Xu XF, Liang RN, Ma HX, Yang HW, Li WL, Huang DM, Sun Y, Hao CF, Du SM, Yang ZW, Wang X, Yan Y, Chen XH, Fu P, Ding CF, Gao YQ, Zhou ZM, Wang CC, Wu TX, Liu JP, Ng EHY, Legro RS, Zhang H. Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA 2017, 317: 2502-2514. PMID: 28655015, PMCID: PMC5815063, DOI: 10.1001/jama.2017.7217.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeControl acupunctureActive acupunctureOvary syndromeLive birthsChinese womenClomiphene groupAcupuncture groupPlacebo groupLow-frequency electrical stimulationActive acupuncture groupControl acupuncture groupSuperficial needle insertionEffect of acupunctureLive birth rateUse of acupunctureMonths of pregnancyNeedle insertionRandomized womenAdverse eventsSecondary outcomesPrimary outcomeClinical evidenceClinical trialsInfertility treatment
2016
Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome
Mumford SL, Legro RS, Diamond MP, Coutifaris C, Steiner AZ, Schlaff WD, Alvero R, Christman GM, Casson PR, Huang H, Santoro N, Eisenberg E, Zhang H, Cedars MI. Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. The Journal Of Clinical Endocrinology & Metabolism 2016, 101: 3288-3296. PMID: 27228369, PMCID: PMC5010565, DOI: 10.1210/jc.2016-1340.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeAnti-Müllerian hormoneSerum anti-Müllerian hormoneAMH levelsOvulation inductionOvary syndromeHigh serum anti-Müllerian hormoneMean AMHSensitivity of folliclesHigher AMH levelsAntral follicle countBody mass indexRandomized clinical trialsOvulation induction medicationsWomen ages 18II trialFollicle countMass indexInduction medicationsInsulin levelsClinical trialsOvulatory responseHealth centersAromatase activityFSH stimulation
2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAcamprosateAdultAlcohol DeterrentsAlcoholismBody Mass IndexDecision TreesDouble-Blind MethodHumansMiddle AgedTaurineTreatment OutcomeUnited StatesConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
2014
Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal Of Medicine 2014, 371: 119-129. PMID: 25006718, PMCID: PMC4175743, DOI: 10.1056/nejmoa1313517.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvary syndromeCongenital anomaliesLive birthsHigh incidenceOvulation rateSignificant between-group differencesCumulative ovulation rateNormal uterine cavityOverall congenital anomaliesBetter pregnancy outcomesPatent fallopian tubesCumulative live birthMajor congenital anomaliesBetween-group differencesYears of ageClomiphene groupLetrozole groupRotterdam criteriaAdverse eventsHot flushesPregnancy outcomesInfertile womenMulticenter trialPrimary outcome
2013
The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Alvero R, Casson P, Christman GM, Huang H, Yan Q, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi R, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, Network I. The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial. Fertility And Sterility 2013, 101: 258-269.e8. PMID: 24156957, PMCID: PMC3899700, DOI: 10.1016/j.fertnstert.2013.08.056.Peer-Reviewed Original ResearchMeSH KeywordsAdultDouble-Blind MethodFemaleFertility Agents, FemaleHumansMaleObesityPolycystic Ovary SyndromePregnancyYoung AdultConceptsAntimüllerian hormone levelsAntral follicle countPolycystic ovary syndromeBaseline characteristicsFollicle countClinical trialsHormone levelsCross-sectional baseline dataCardiovascular risk factorsEffect of obesityMost metabolic parametersMean semen parametersFSH ratioFSH levelsII studyOvarian volumeOvary syndromeMetabolic syndromeTreatment regimensRisk factorsHealth centersMetabolic dysfunctionMetabolic parametersMAIN OUTCOMETreatment groups
2012
Altering Hirsutism Through Ovulation Induction in Women With Polycystic Ovary Syndrome
Roth LW, Huang H, Legro RS, Diamond MP, Coutifaris C, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Zhang H, Schlaff WD. Altering Hirsutism Through Ovulation Induction in Women With Polycystic Ovary Syndrome. Obstetrics And Gynecology 2012, 119: 1151-1156. PMID: 22617579, PMCID: PMC3360417, DOI: 10.1097/aog.0b013e31825618fb.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeFerriman-Gallwey scoreClomiphene citrateOvary syndromePolycystic Ovary Syndrome IDouble-blind trialDuration of treatmentAbsence of ovulationHirsutism scoreOvulation inductionHirsute womenHirsutismSecondary analysisMetforminWomenGroup assignmentSignificant decreaseSignificant differencesTreatmentSyndromeInfertilityGreater improvementScoresPregnancyGroupEndometrial Shedding Effect on Conception and Live Birth in Women With Polycystic Ovary Syndrome
Diamond MP, Kruger M, Santoro N, Zhang H, Casson P, Schlaff W, Coutifaris C, Brzyski R, Christman G, Carr BR, McGovern PG, Cataldo NA, Steinkampf MP, Gosman GG, Nestler JE, Carson S, Myers EE, Eisenberg E, Legro RS. Endometrial Shedding Effect on Conception and Live Birth in Women With Polycystic Ovary Syndrome. Obstetrics And Gynecology 2012, 119: 902-908. PMID: 22525900, PMCID: PMC4007263, DOI: 10.1097/aog.0b013e31824da35c.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeLive birth rateAnovulatory cyclesEndometrial sheddingClomiphene citrateOvary syndromeLive birthsEunice Kennedy Shriver National InstituteBirth rateCommon clinical practiceOccurrence of ovulationRate of conceptionAnovulatory womenOvarian stimulationOvulation inductionSpontaneous mensesProgestin withdrawalChild healthClinical practiceNetwork trialSecondary analysisOvulation rateMetforminAdverse effectsWomenThe Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, Christman GM, Coutifaris C, Taylor HS, Eisenberg E, Santoro N, Zhang H, Network F. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemporary Clinical Trials 2012, 33: 470-481. PMID: 22265923, PMCID: PMC3312939, DOI: 10.1016/j.cct.2011.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsChi-Square DistributionClomipheneDouble-Blind MethodFemaleFertility Agents, FemaleHealth Status IndicatorsHirsutismHumansHyperandrogenismInfertility, FemaleLetrozoleMiddle AgedNitrilesOvulation InductionPolycystic Ovary SyndromePregnancyQuality of LifeResearch DesignTriazolesWomen's HealthYoung AdultConceptsPolycystic ovary syndromeClomiphene citrateOvary syndromeInfertile womenTreatment armsDouble-blind clinical trialSelective estrogen receptor modulatorsMajor infertility factorOral clomiphene citrateMultiple pregnancy rateFirst-line treatmentLive birth rateEstrogen receptor modulatorsDifferent treatment armsTreatment of infertilityPoor ovulatory responseEndometrial effectsII trialII studyLine treatmentInfertility factorsProgestin withdrawalAromatase inhibitorsClinical trialsFemale infertility
2011
Estimating rates of multiple gestation pregnancies: Sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial
Diamond MP, Mitwally M, Casper R, Ager J, Legro RS, Brzyski R, Casson P, Eisenberg E, Zhang H, Network F. Estimating rates of multiple gestation pregnancies: Sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial. Contemporary Clinical Trials 2011, 32: 902-908. PMID: 21787883, PMCID: PMC3708642, DOI: 10.1016/j.cct.2011.07.009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAromatase InhibitorsClomipheneDose-Response Relationship, DrugDouble-Blind MethodFemaleFertility Agents, FemaleGonadotropinsHumansInfant, NewbornInfertilityLetrozoleMaleNitrilesOvulation InductionPregnancyPregnancy OutcomePregnancy, MultipleProspective StudiesTreatment OutcomeTriazolesYoung AdultConceptsMultiple Intrauterine GestationsMultiple gestation pregnanciesOvulation inductionUnexplained infertilityGestation pregnanciesIntrauterine gestationMultiple gestationsComparable pregnancy ratesMono-follicular developmentOvarian stimulation (AMIGOS) trialOvarian hyperstimulation syndromePregnancy success ratePublic health benefitsExpense of careHyperstimulation syndromeClomiphene citrateNeonatal morbidityPreterm laborFertility medicationsPreterm infantsIntrauterine inseminationStimulation trialsAromatase inhibitorsPregnancy rateGestation
1998
A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome
Peterson B, Zhang H, Anderson G, Leckman J. A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome. Journal Of Clinical Psychopharmacology 1998, 18: 324-331.. PMID: 9690699, DOI: 10.1097/00004714-199808000-00013.Peer-Reviewed Original ResearchConceptsAndrogen receptor blockadeReceptor blockadeCrossover trialHormone levelsSyndrome patientsSelective androgen receptor antagonistAdult TS subjectsTreatment of ticsTourette syndrome patientsTic symptom severitySerious side effectsAndrogen receptor antagonistSymptom severity ratingsTS prevalenceClinic visitsFlutamide administrationEndocrine findingsObsessive-compulsive disorderReceptor antagonistAndrogen receptorPhysiologic compensationTherapeutic effectPhysiologic mechanismsSide effectsTourette syndrome